T1	Premise 44 240	75-year-old male, hypertensive on treatment with enalapril (20 mg/day), who consults for deterioration of general condition, bitemporal headache and mandibular claudication of 3 weeks of evolution
T2	Premise 242 331	In addition, in the last hours, he refers two episodes of amaurosis fugax of the left eye
T3	Premise 333 422	Physical examination revealed thickening and absence of pulse in the left temporal artery
T4	Premise 424 486	Analysis: CRP 6 mg/dl (VN <1); hemoglobin 10.5 g/dl; ESR 92 mm
T5	Premise 488 506	Chest X-ray normal
T6	Claim 596 722	Rituximab should be administered, since glucocorticoids have been relegated to second-line treatment due to their side effects
T7	Claim 727 853	Tocilizumab has been shown to be effective in reducing recurrences and cumulative prednisone dose in more than 50% of patients
T8	Claim 858 1032	In the presence of ischemic symptoms, and in order not to worsen the vascular risk of the patient, the use of glucocorticoids at doses higher than 30 mg/day should be avoided
T9	Claim 1037 1162	In conjunction with glucocorticoid boluses of 1 g/day, infliximab should be used as a first-line drug for remission induction
T10	Claim 1189 1226	Clinical case of giant cell arteritis
T11	Claim 1228 1422	Corticosteroid therapy remains the first choice (answer 1 incorrect), to be administered as pulses (doses differ according to the literature, but at least 125 mg/d) in case of ocular involvement
T13	Treatment 596 605	Rituximab
T14	Marker 630 635	since
T15	Treatment 636 651	glucocorticoids
T16	Claim 1445 1588	The current treatment of choice for corticosteroid sparing is Tocilizumab (answer 4 incorrect), which has also been shown to reduce recurrences
T17	Claim 1520 1538	answer 4 incorrect
R3	Support Ent1:T16 Ent2:T17	
R4	Attack Ent1:T17 Ent2:T9	
T12	Claim 1277 1295	answer 1 incorrect
R1	Attack Ent1:T12 Ent2:T6	
T18	Claim 1424 1442	answer 3 incorrect
R2	Attack Ent1:T18 Ent2:T8	
R5	Support Ent1:T11 Ent2:T12	
R6	Support Ent1:T12 Ent2:T18	
T19	Claim 1590 1606	answer 2 correct
R7	Support Ent1:T16 Ent2:T19	
R8	Support Ent1:T19 Ent2:T7	
T20	Treatment 1507 1518	Tocilizumab
T21	Treatment 1228 1250	Corticosteroid therapy
T22	Treatment 727 738	Tocilizumab
T23	Treatment 809 819	prednisone
T24	Treatment 968 1014	glucocorticoids at doses higher than 30 mg/day
T25	Marker 1025 1032	avoided
T26	Treatment 1057 1090	glucocorticoid boluses of 1 g/day
T27	Treatment 1092 1102	infliximab
